Usage Information
Abstract
The present study aimed to explore the role and possible underlying mechanisms of histone lactylation (Kla) modifications in diabetes-associated cognitive impairment (DACD). In this study, behavioral tests, H&E staining, and immunohistochemistry were used to evaluate cognitive function and the extent of cerebral tissue injury. We quantified the levels of lactic acid and pan-lysine Kla (Pan-Kla) in the brains of type 2 diabetes mellitus (T2DM) mice and in high glucose–treated microglia. We also identified all Kla sites in isolated microglia. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were subsequently conducted to identify the functions and pathways that were enriched at the differentially expressed modification sites. Cleavage under targets and tagmentation (CUT&Tag) technology was used to identify candidate genes that are regulated by histone H3 lactylated at Lys-18 (H3K18la). siRNA and H3K18R mutant sequences were used to knock down crucial components in key signaling pathways to assess the effects of histone Kla on microglial polarization. We found that lactic acid levels were significantly greater in the brains of T2DM mice and high glucose–treated microglia than in those of their corresponding controls, which increased the level of Pan-Kla. We discovered that lactate can directly stimulate an increase in H3K18la. The global landscape of the lactylome reveals information about modification sites, indicating a correlation between the upregulation of H3K18la and protein Kla and Toll-like receptor (TLR) signaling. CUT&Tag demonstrated that enhanced H3K18la directly stimulates the NF-κB signaling pathway by increasing binding to the promoter of TLR4, thereby promoting M1 microglial polarization. The present study demonstrated that enhanced H3K18la directly stimulates TLR4 signaling to promote M1 microglial polarization, thereby facilitating DACD phenotypes. Targeting such loop may be a potential therapeutic approach for the treatment of DACD.
Authors
Ying Yang, Fei Chen, Lulu Song, Liping Yu, Jinping Zhang, Bo Zhang
Usage data is cumulative from November 2025 through February 2026.
| Usage | JCI | PMC |
|---|---|---|
| Text version | 1,822 | 0 |
| 452 | 0 | |
| Figure | 522 | 0 |
| Supplemental data | 347 | 0 |
| Citation downloads | 197 | 0 |
| Totals | 3,340 | 0 |
| Total Views | 3,340 | |
Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.
Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.
